

Special Issue

Neurofibromatosis Type 1 (NF1) Tumor Spectrum

Message from the Guest Editors

We aim to address both basic and pre-clinical research to enhance our understanding of these complex tumors. Furthermore, we will highlight groundbreaking advancements in diagnostics, emphasizing the crucial role of genetic and molecular profiling in identifying at-risk patients and developing individualized treatment strategies. The issue will also feature discussions on the latest therapeutic innovations—such as targeted therapies, immunotherapies, and multimodal treatment regimens—aimed at improving outcomes for this vulnerable patient population. Additionally, this Special Issue will address important topics such as prognostic factors, survival rates, and the complexities involved in managing the various types of tumors related to NF1. By shedding light on the biology, clinical strategies, and cutting-edge treatments for these NF tumor spectra, this collection aims to enhance understanding and advance the quest for better care for those affected by NF1. We welcome original research articles and reviews.

Guest Editors

Dr. Jay Pundavela
Dr. Kyle B. Williams
Dr. R. Taylor Sundby

Deadline for manuscript submissions

closed (31 March 2026)



Current Oncology

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 6.1
Indexed in PubMed



mdpi.com/si/227788

Current Oncology
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
currentoncology@mdpi.com

[mdpi.com/journal/
currentoncology](https://mdpi.com/journal/currentoncology)





Current Oncology

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 6.1
Indexed in PubMed



[mdpi.com/journal/
currenocol](https://mdpi.com/journal/currenocol)



About the Journal

Message from the Editor-in-Chief

I am honored and enthusiastic to serve as Editor-in-Chief of *Current Oncology*. Since its establishment in 1994, *Current Oncology* has been playing an important role in the advancement of cancer care by disseminating new knowledge in the cancer care continuum. *Current Oncology* is affiliated with several key cancer societies and provides a global platform to share scientific progress in oncology. We strive for high standards and work together to maintain a rigorous and unbiased peer review process to publish high-quality articles. We have an outstanding editorial team which is committed to the success of *Current Oncology*.

Editor-in-Chief

Prof. Dr. Shahid Ahmed

1. College of Medicine, University of Saskatchewan, Saskatoon, SK S7N5E5, Canada
 2. Saskatchewan Cancer Agency, Saskatoon Cancer Center, Saskatoon, SK S7N5H5, Canada
-

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)